Emergent BioSolutions Inc.
EBS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $469,224 | $345,796 | $264,384 | $518,152 |
| - Cash | $245,500 | $267,300 | $149,100 | $99,500 |
| + Debt | $663,100 | $667,800 | $665,700 | $663,700 |
| Enterprise Value | $886,824 | $746,296 | $780,984 | $1,082,352 |
| Revenue | $231,100 | $140,900 | $222,200 | $194,700 |
| % Growth | 64% | -36.6% | 14.1% | – |
| Gross Profit | $139,400 | $60,700 | $119,400 | $136,500 |
| % Margin | 60.3% | 43.1% | 53.7% | 70.1% |
| EBITDA | $96,200 | $23,500 | $75,200 | $21,000 |
| % Margin | 41.6% | 16.7% | 33.8% | 10.8% |
| Net Income | $51,200 | -$12,000 | $68,000 | -$31,300 |
| % Margin | 22.2% | -8.5% | 30.6% | -16.1% |
| EPS Diluted | 0.91 | -0.22 | 1.19 | -0.59 |
| % Growth | 513.6% | -118.5% | 301.7% | – |
| Operating Cash Flow | -$2,300 | $106,400 | -$11,200 | -$79,900 |
| Capital Expenditures | -$3,400 | -$2,900 | -$3,600 | -$1,700 |
| Free Cash Flow | -$5,700 | $103,500 | -$14,800 | -$81,600 |